We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.23% | 29.75 | 29.55 | 30.50 | 30.05 | 29.53 | 29.80 | 5,444,214 | 21:57:01 |
From May 2019 to May 2024
By Michael Dabaie
Xencor Inc. (XNCR) said Tuesday it has entered a research and license agreement with Genentech, part of Roche (RHHBY).
Genentech will pay Xencor $120 million upfront, and Xencor will be eligible to receive up to $180 million in development milestones per program and profit share from commercialized medicines.
The deal aims to develop and commercialize novel IL-15 cytokine therapeutics.
"We believe cytokine therapy will play an important role in the treatment of a wide range of diseases, including cancer," said James Sabry, global head of pharma partnering for Roche.
Xencor shares were recently up 4% to $37.88.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
February 05, 2019 13:14 ET (18:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
